How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature

About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD) and such defect accounts for synthetic lethality mechanism of PARP inhibitors (PARP-i). Several clinical trials have shown how BRCA and HRD m...

Full description

Bibliographic Details
Main Authors: Martina Arcieri, Veronica Tius, Claudia Andreetta, Stefano Restaino, Anna Biasioli, Elena Poletto, Giuseppe Damante, Alfredo Ercoli, Lorenza Driul, Anna Fagotti, Domenica Lorusso, Giovanni Scambia, Giuseppe Vizzielli
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
ovarian cancer
homologous recombination deficiency
BRCA protein
BRCAness
HRD testing
PARP inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1335196/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1335196/full

Similar Items